Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Ulisse, Salvatore ^a   Baldini, Enke ^a   Mottolese, Marcella ^b   Sentinelli, Steno ^b   Gargiulo, Patrizia ^a   Valentina, Brancato ^a   Sorrenti, Salvatore ^c   Di Benedetto, Anna ^b   De Antoni, Enrico ^c   D'Armiento, Massimino ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE RECEPTOR; PLAUR PROTEIN, HUMAN; SERPINE1 PROTEIN, HUMAN; UROKINASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEMINOMA; TUMOR VOLUME; WESTERN BLOTTING; ZYMOGRAPHY; CANCER STAGING; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; ITALY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TESTIS TUMOR; UPREGULATION;

ADULT; BLOTTING, WESTERN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; ITALY; MALE; MIDDLE AGED; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEMINOMA; TESTICULAR NEOPLASMS; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 77950952820     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-151     Document Type: Article

References (39)

1. Ulbright TM. Germ cell neoplasms of the testis. Am J Surg Pathol 1993, 17:1075-1091. 10.1097/00000478-199311000-00001, 8214253.
2. Looijenga LH, Oosterhuis JW. Pathogenesis of testicular germ cell tumors. Rev Reprod 1999, 4:90-100. 10.1530/ror.0.0040090, 10357096.
3. von Eyben FE, Jacobsen GK, Skotheim RI. Microinvasive germ cell tumor of the testis. Virch Arch 2005, 447:610-625.
4. Bergstrom R, Adami H-O, Mohner M, Zatonski W, Storm H, Ekbom A, Tretli S, Teppo L, Akre O, Hakulinen T. Increase in testicular cancer in six European countries: a birth cohort phenomenon. J Natl Cancer Instit 1996, 88:727-733.
5. Bunge G, Bradbury JT. An early human seminoma. JAMA 1965, 193:960-962.
6. Skakkebaek NE. Carcinoma in situ of the testis: frequency and relationship to invasive germ cell tumours in infertile men. Histopathol 1978, 2:157-170.
7. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997, 72:1-2. 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z, 9212216.
8. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004, 10:39-49. 10.2174/1381612043453559, 14754404.
9. Medcalf RL, Stasinopoulos SJ. The undecided serpin. The ins and out of plasminogen activator inhibitor type 2. FEBS J 2005, 272:4858-4867. 10.1111/j.1742-4658.2005.04879.x, 16176260.
10. Croucher DR, Saunders DN, Lobov S, Ranson M. Revisiting the biological roles of PAI-2 (SERPINB2) in cancer. Nat Rev Cancer 2008, 8:535-545. 10.1038/nrc2400, 18548086.
11. Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anticancer therapy. Curr Cancer Drug Targ 2009, 9:32-71.
12. Sprenger ED, Kluft C. Plasminogen activator inhibitors. Blood 1987, 69:381-387.
13. España F, Estelles A, Fernandez PJ, Gilabert J, Sanchez-Cuenca J, Griftin JH. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma. Thromb Haemost 1993, 70:989-994.
14. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Sem Cancer Biol 2000, 10:415-433.
15. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003, 92:827-839. 10.1161/01.RES.0000070112.80711.3D, 12730128.
16. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008, 214:283-293. 10.1002/path.2282, 18095256.
17. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumor markers for the individualised management of patient with cancer. Clin Biochem 2004, 37:541-548. 10.1016/j.clinbiochem.2004.05.013, 15234235.
18. Pepper MS. Role of matrix metalloproteinases and plasminogen activator-plasmin system in angiogenesis. Arter Thromb Vascular Biol 2001, 21:1104-1117.
19. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3:932-943. 10.1038/nrm977, 12461559.
20. Choong PFM, Nadesapillai APW. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 2003, 415S:S46-S58.
21. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004, 24:13-19. 10.1002/med.10054, 14595671.
22. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Hofler H, Janicke F, Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997, 78:285-296.
23. Duffy MJ. Urokinase plasminogen activator and its inhibitor PAI-1 as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002, 48:1194-1197.
24. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004, 6:109-118. 10.1186/bcr777, 400674, 15084231.
25. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002, 94:116-128.
26. Pillay V, Dass CR, Choong PF. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 25:33-39. 10.1016/j.tibtech.2006.10.011, 17084931.
27. Konaka H, Koshida K, Endo Y, Uchibayashi T, Sasaki T, Namiki M. A human seminoma xenograft model with regional lymph node metastasis. J Urol 1999, 161:342-348. 10.1016/S0022-5347(01)62143-8, 10037435.
28. Okada K, Katagiri T, Tsunoda T, Mizutani Y, Suzuki Y, Kamada M, Fujioka T, Shuin T, Miki T, Nakamura Y. Analysis of gene-expression profiles in testicular seminomas using a genome-wide cDNA microarray. Int J Oncol 2003, 23:1615-1635.
29. Chomczynsky P, Sacchi P. Single step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
31. Ulisse S, Rucci N, Piersanti D, Carosa E, Graziano FM, Pavan A, Ceddia P, Arizzi M, Muzi P, Cironi L, Gnessi L, D'Armiento M, Jannini EA. Regulation by thyroid hormone of the expression of basement membrane components in rat prepubertal Sertoli cells. Endocrinology 1998, 139:741-747. 10.1210/en.139.2.741, 9449648.
32. Bajou K, Lewalle JM, Martinez CR, Soria C, Lu H, Noel A, Foidart JM. Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. Int J Cancer 2002, 100:501-506. 10.1002/ijc.10487, 12124797.
33. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
34. Skotheim RI, Lind GE, Monni O, Neslands JM, Abeler VM, Fossa SD, Duale N, Brunborg G, Kallioniemi O, Andrews PW, Lothe RA. Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res 2005, 65:5588-5598. 10.1158/0008-5472.CAN-05-0153, 15994931.
35. Kumar S, Baglioni C. Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type 2. J Biol Chem 1991, 266:20690-20694.
36. Dickinson JL, Bates EJ, Ferrante A, Antalis TM. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J Biol Chem 1995, 270:27894-27904. 10.1074/jbc.270.40.23239, 7499264.
37. Balboni GC, Barni T, Serio M, Vannelli GC. Plasminogen activator and inhibin in the human testis. An immunohistochemical investigation. Bull Assoc Anat (Nancy) 1991, 75:123-126.
38. Diez-Torre A, Silvan U, De Wever O, Bruynell E, Mareel M, Arechaga J. Germinal tumor invasion and the role of testicular stroma. Int J Dev Biol 2004, 48:545-557. 10.1387/ijdb.041897ad, 15349829.
39. Warde P, Gospodarowicz MK, Banerjee D, Panzarella T, Sugar L, Catton CN, Sturgeon JFG, Moore M, Jewett MAS. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 1997, 157:1705-1710. 10.1016/S0022-5347(01)64839-0, 9112510.